Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Antineoplastic Agents
/ therapeutic use
Cisplatin
/ therapeutic use
Head and Neck Neoplasms
/ radiotherapy
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Radiation Tolerance
/ drug effects
Radiation-Sensitizing Agents
/ therapeutic use
Radioimmunotherapy
/ methods
Randomized Controlled Trials as Topic
Squamous Cell Carcinoma of Head and Neck
/ radiotherapy
Abscopal effect
Cancers ORL
Cancers des voies aéro-digestives supérieures
Carcinome épidermoïde
Chemoradiotherapy
Chimioraiothérapie
Cisplatin
Cisplatine
Effet abscopal
Head and neck cancer
Immune checkpoint inhibitors
Immunotherapy
Immunothérapie
Inhibiteurs de checkpoint
PD1
PDL1
Radiotherapy
Radiothérapie
Squamous cell carcinoma
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
25
07
2021
revised:
16
08
2021
accepted:
18
08
2021
pubmed:
30
10
2021
medline:
15
12
2021
entrez:
29
10
2021
Statut:
ppublish
Résumé
Chemoradiotherapy with concurrent cisplatin has been the standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC) for over 20 years. Recently, immunotherapy, a new therapeutic class, has emerged for patients with recurrent or metastatic HNSCC and has significantly extended their survival. Will it bring the same benefit to patients with localized tumors? There is a strong rationale for combining radiation therapy and checkpoint inhibitors for HNSCC. Indeed, radiation therapy can have both immunostimulatory and immunomodulatory effects. This is what explains the famous abscopal effect. The aim of this review is to present the data available on the combination of radiation therapy and immunotherapy for HNSCC.
Identifiants
pubmed: 34711485
pii: S1278-3218(21)00252-3
doi: 10.1016/j.canrad.2021.08.018
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Radiation-Sensitizing Agents
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
811-815Informations de copyright
Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.